However, the overall safety profile of taspoglutide was clearly worse than exenatide with respect to gastrointestinal tolerability, systemic allergic reactions, and injection-site reactions.

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

Glucose-lowering treatments for which efficacy and safety have been evaluated in completed randomized clinical trials in children and adolescents with T2D are extremely limited. This is in stark ...